Portage Biotech Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $1.34 |
| Prev. Close | $1.41 |
| EPS | -6.69 |
| Dividend | $0.00 |
| Next Earnings Date | May 31, 2023 |
| Dividend Yield % | - |
| Market Cap | $27.87M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 1.34 | 1.41 |
| 52 Week Range | 1.21 | 7.67 |
| Ratios | |
|---|---|
| P/B Ratio | 0.38 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$197.49M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -92.36% |
| EPS | -6.69 |
Score Breakdown
All Score (51 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| PRTG | Market | |
|---|---|---|
| Value | 64 | 42 |
| Quality | 41 | 46 |
| Ownership | 18 | 39 |
| Growth | 47 | 44 |
| Dividends | - | 32 |
All Score (51 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Portage Biotech Inc. (PRTG)
Portage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products. The company's product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Ian B. Walters M.B.A., M.D.
- Headquarters
- Tortola
- Employees
- 7
Keep an eye on Portage Biotech Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.